Skip to search formSkip to main contentSkip to account menu

Chromogranin A (344-364) fragment

Known as: catestatin, chromogranin A (344-364) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Abstract Catestatin, a catecholamine-release inhibitory peptide, has multiple cardiovascular activities. Conflicting results have… 
Review
2018
Review
2018
It is increasingly clear that inflammatory diseases and cancers are influenced by cleavage products of the pro-hormone… 
2012
2012
New endogenous antimicrobial peptides (AMPs) derived from chromogranin A (CgA) are secreted by nervous, endocrine and immune… 
Review
2012
Review
2012
Chromogranin A (CgA) is produced by cells of the sympathoadrenal system and by human ventricular myocardium. In the clinical… 
2011
2011
Screening patients with stage B heart failure(HF) may be one strategy for reducing human morbidity. To describe catestatin levels… 
2010
2010
BACKGROUND Obstructive sleep apnea (OSA) is common in children and leads to multiple end-organ morbidities induced by the… 
Highly Cited
2009
Highly Cited
2009
We reported previously that chromogranin A (Chga) knockout (KO) mice are hypertensive and hyperadrenergic. Here we sought to… 
Highly Cited
2002
Highly Cited
2002
The catestatin fragment of chromogranin A is the first known endogenous compound able to inhibit catecholamine release elicited…